Analysis of the activities of cord blood banks in the Russian Federation

Abstract

This review aimed to analyze the activities of all state and commercial cord blood banks in the Russian Federation, to estimate the total number of cord blood samples in storage at the beginning of 2023, and to determine the practical use of the biomaterial for treatment — allogeneic and autologous transplants for oncohematological diseases, as well as for scientific research in the field of regenerative medicine for the entire period of the banks' operation, which is twenty years.

To date, there are 12 cord blood banks providing personal, public or mixed storage of samples. At the moment, up to 26,000 cord blood samples are in public storage, and about 75,000 samples are in personal storage.

As part of the review, the main and additional services provided by banks, as well as their current cost, were studied. The average cost of cord blood sample collection in the Russian Federation is 62,500 rubles, and the average annual cost of storage is 6,000 rubles. The main market indicators, trends, key problems of biobanking and prospects for the use of cord blood cells in the Russian Federation in the coming years are considered in detail.

Separately, data on the prospects for the use of umbilical cord mesenchymal stem cells, a widely studied biomaterial, which, like cord blood, can be collected after childbirth and cryopreserved for long-term storage, are briefly presented. Stem cells of the umbilical cord are being actively studied in the field of regenerative medicine due to their properties to restore cartilaginous muscle and bone tissue, stimulate the growth of new blood vessels, and block autoimmune reactions.

In addition, the current tasks and results of the activities of Ruscord, an association of specialists and organizations in the field of procurement, storage, use of cord blood cells and cell technologies, which over several years of its activity has already made a significant contribution to the development of the biobanking market, were analyzed. In September 2020, a unified standard for the collection, processing, storage and issuance of cord blood for use was approved — the Russian standard RUSCORD.

Keywords

umbilical cord blood / cord blood bank / transplantation / hematopoietic stem cells

References

[1] Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconis anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174–1184. doi: 10.1056/NEJM198910263211707

[2] Gluckman E., Broxmeyer H.A., Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconis anemia by means of umbilical-cord blood from an HLA-identical sibling // N Engl J Med. 1989. Vol. 321, N 17. P. 1174–1184. doi: 10.1056/NEJM198910263211707

[3] Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045–1053. doi: 10.3324/haematol.2021.279189

[4] Niederwieser D., Baldomero H., Bazuaye N., et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors // Haematologica. 2022. Vol. 107, N 5. P. 1045–1053. doi: 10.3324/haematol.2021.279189

[5] Dumont-Lagacé M, Feghaly A, Meunier MC, et al. UM171 expansion of cord blood improves donor availability and HLA matching for all patients, including minorities. Transplant Cell Ther. 2022;28(7):410.e1–410.e5. doi: 10.1016/j.jtct.2022.03.016

[6] Dumont-Lagacé M., Feghaly A., Meunier M.C., et al. UM171 expansion of cord blood improves donor availability and HLA matching for all patients, including minorities // Transplant Cell Ther. 2022. Vol. 28, N 7. P. 410.e1–410.e5. doi: 10.1016/j.jtct.2022.03.016

[7] https://www.rdkm.rusfond.ru/ [Internet]. Aktivacija donora: chto pochem v donorskih registrah — nashem Nacional’nom i inostrannyh. Available from: https://rdkm.rusfond.ru/registr/059 (In Russ).

[8] https://www.rdkm.rusfond.ru/ [интернет]. Активация донора: что почем в донорских регистрах — нашем Национальном и иностранных. Доступ по ссылке: https://rdkm.rusfond.ru/registr/059

[9] https://www.asi.org.ru/ [Internet]. Kak stat’ donorom kostnogo mozga i zachem jeto nuzhno. Agentstvo social’noj informacii. Available from: https://www.asi.org.ru/2018/10/29/kakstatdonoro/ (In Russ).

[10] https://www.asi.org.ru/ [интернет]. Как стать донором костного мозга и зачем это нужно. Агентство социальной информации. Доступ по ссылке: https://www.asi.org.ru/2018/10/29/kakstatdonoro/

[11] Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138(16):1429–1440. doi: 10.1182/blood.2021011719

[12] Horwitz M.E., Stiff P.J., Cutler C., et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study // Blood. 2021. Vol. 138, N 16. P. 1429–1440. doi: 10.1182/blood.2021011719

[13] Wagner JE Jr, Brunstein CG, Boitano AE, et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2015;18(1):144–155. doi: 10.1016/j.stem.2015.10.004

[14] Wagner J.E. Jr., Brunstein C.G., Boitano A.E., et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft // Cell Stem Cell. 2015. Vol. 18, N 1. P. 144–155. doi: 10.1016/j.stem.2015.10.004

[15] https://www.fda.gov/ [Internet]. FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cel

[16] https://www.fda.gov/ [Internet]. FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. Доступ по ссылке: https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cel

[17] https://www.gamida-cell.com/ [Internet]. Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) receives FDA approval. Available from: https://statistics.wmda.info/ https://investors.gamida-cell.com/news-events/press-releases/news-release-details/gamida-cells-allogeneic-cell-therapy-omisirger

[18] https://www.gamida-cell.com/ [Internet]. Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) receives FDA approval. Доступ по ссылке: https://statistics.wmda.info/ https://investors.gamida-cell.com/news-events/press-releases/news-release-details/gamida-cells-allogeneic-cell-therapy-omisirger

[19] https://statistics.wmda.info/ [Internet]. WMDA. Total Number of Donors and Cord blood units. Available from: https://statistics.wmda.info/

[20] https://statistics.wmda.info/ [Internet]. WMDA. Total Number of Donors and Cord blood units. Доступ по ссылке: https://statistics.wmda.info/

[21] 11. https://www.researchandmarkets.com/ [Internet]. Stem Cell/Cord Blood Banking Global Market Report 2023. Available from: https://www.researchandmarkets.com/reports/5735457/stem-cellcord-blood-banking-global-market-report

[22] https://www.researchandmarkets.com/ [Internet]. Stem Cell/Cord Blood Banking Global Market Report 2023. Доступ по ссылке: https://www.researchandmarkets.com/reports/5735457/stem-cellcord-blood-banking-global-market-report

[23] Litvinova LS, Goncharov AG, Shupletsova VV, et al. Analysis of the legal regulation of the circulation of cord blood and its components in the Russian Federation and abroad. Genes and cells. 2020;15(4):88–94. (In Russ). doi: 10.23868/202012014

[24] Литвинова Л.С., Гончаров А.Г., Шуплецова В.В., и др. Анализ правового регулирования обращения пуповинной крови и ее компонентов в Российской Федерации и за рубежом // Гены и клетки. 2020. Т. 15, N 4. С. 88–94. doi: 10.23868/202012014

[25] https://www.publication.pravo.gov.ru/ [Internet]. Order of the Ministry of Health of the Russian Federation dated December 12, 2018 No. 875n “Ob utverzhdenii Porjadka okazanija medicinskoj pomoshhi pri zabolevanijah (sostojanijah), dlja lechenija kotoryh primenjaetsja transplantacija (peresadka) kostnogo mozga i gemopojeticheskih stvolovyh kletok i vnesenii izmenenija v Porjadok okazanija medicinskoj pomoshhi po profilju “hirurgija (transplantacija organov i (ili) tkanej cheloveka)””. Available from: http://publication.pravo.gov.ru/Document/View/0001201901090037 (In Russ).

[26] https://www.publication.pravo.gov.ru/ [интернет]. Приказ Министерства здравоохранения Российской Федерации от 12.12.2018 № 875н «Об утверждении Порядка оказания медицинской помощи при заболеваниях (состояниях), для лечения которых применяется трансплантация (пересадка) костного мозга и гемопоэтических стволовых клеток и внесении изменения в Порядок оказания медицинской помощи по профилю “хирургия (трансплантация органов и (или) тканей человека)”». Доступ по ссылке: http://publication.pravo.gov.ru/Document/View/0001201901090037

[27] Tjumina OV, Hurcilava OG, Smoljaninov AB. Pupovinnaja krov’: zagotovka, hranenie, transplantacija i regenerativnaja medicina. Saint Petersburg: Sintez Buk, Nauka; 2012. 352 p. (In Russ).

[28] Тюмина О.В., Хурцилава О.Г., Смолянинов А.Б. Пуповинная кровь: заготовка, хранение, трансплантация и регенеративная медицина. Санкт-Петербург : Синтез Бук, Наука, 2012. 352 с.

[29] https://www.gemabank.ru/ [Internet]. Available from: https://gemabank.ru/predstaviteli (In Russ).

[30] https://www.gemabank.ru/ [интернет]. Роддома и перинатальные центры. Доступ по ссылке: https://gemabank.ru/predstaviteli

[31] https://www.gemabank.ru/ [Internet]. Publichnoe akcionernoe obshhestvo «Mezhdunarodnyj Medicinskij Centr Obrabotki i Kriohranenija Biomaterialov» (PAO «MMCB»), godovoj otchet po itogam 2020 goda. Moskva, 2021. Available from: https://invest.gemabank.ru/download/issuer_report/Annual_report_20.pdf (In Russ).

[32] https://www.gemabank.ru/ [интернет]. Публичное акционерное общество «Международный Медицинский Центр Обработки и Криохранения Биоматериалов» (ПАО «ММЦБ»), годовой отчет по итогам 2020 года. Москва, 2021. Доступ по ссылке: https://invest.gemabank.ru/download/issuer_report/Annual_report_20.pdf

[33] https://www.viacord.com/ [Internet]. ViaCORD: Consumer CB Use Summary. Available from: https://www.viacord.com/Images/Consumer%20CB%20Use%20Summary%20-%20Over%20500-0920_tcm117-230237.pdf

[34] https://www.viacord.com/ [Internet]. ViaCORD: Consumer CB Use Summary. Доступ по ссылке: https://www.viacord.com/Images/Consumer%20CB%20Use%20Summary%20-%20Over%20500-0920_tcm117-230237.pdf

[35] Ulus AT, Mungan C, Kurtoglu M, et al. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART trial). Int J Stem Cells. 2020;13(3):364–376. doi: 10.15283/ijsc20075

[36] Ulus A.T., Mungan C., Kurtoglu M., et al. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART trial) // Int J Stem Cells. 2020. Vol. 13, N 3. P. 364–376. doi: 10.15283/ijsc20075

[37] Kahraman NS, Oner A. Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial. Int J Ophthalmol. 2020;13(9):1423–1429. doi: 10.18240/ijo.2020.09.14

[38] Kahraman N.S., Oner A. Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial // Int J Ophthalmol. 2020. Vol. 13, N 9. P. 1423–1429. doi: 10.18240/ijo.2020.09.14

[39] Zhang J, Lv S, Liu X, et al. Umbilical cord mesenchymal stem cell treatment for crohn’s disease: a randomized controlled clinical trial. Gut Liver. 2018;12(1):73–78. doi: 10.5009/gnl17035

[40] Zhang J., Lv S., Liu X., et al. Umbilical cord mesenchymal stem cell treatment for crohn’s disease: a randomized controlled clinical trial // Gut Liver. 2018. Vol. 12, N 1. P. 73–78. doi: 10.5009/gnl17035

[41] Wang L, Huang S, Li S, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. Drug Des Devel Ther. 2019;13:4331–4340. doi: 10.2147/DDDT.S225613

[42] Wang L., Huang S., Li S., et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study // Drug Des Devel Ther. 2019. Vol. 13. P. 4331–4340. doi: 10.2147/DDDT.S225613

[43] Jia Y, Shu X, Yang X, et al. Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis. Stem Cell Res Ther. 2020;11(1):277. doi: 10.1186/s13287-020-01787-4

[44] Jia Y., Shu X., Yang X., et al. Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis // Stem Cell Res Ther. 2020. Vol. 11, N 1. P. 277. doi: 10.1186/s13287-020-01787-4

[45] Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl. Med. 2021;10(5):660–673. doi: 10.1002/sctm.20-0472

[46] Lanzoni G., Linetsky E., Correa D., et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial // Stem Cells Transl Med. 2021. Vol. 10, N 5. P. 660–673. doi: 10.1002/sctm.20-0472

[47] Carlsson PO, Espes D, Sisay S, et al. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a phase I/II randomised double-blind placebo-controlled trial. Diabetologia. 2023;66(8):1431–1441. doi: 10.1007/s00125-023-05934-3

[48] Carlsson P.O., Espes D., Sisay S., et al. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a phase I/II randomised double-blind placebo-controlled trial // Diabetologia. 2023. Vol. 66, N 8. P. 1431–1441. doi: 10.1007/s00125-023-05934-3

[49] Zang L, Li Y, Hao H, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Res Ther. 2022;13(1):180. doi: 10.1186/s13287-022-02848-6

[50] Zang L., Li Y., Hao H., et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial // Stem Cell Res Ther. 2022. Vol. 13, N 1. P. 180. doi: 10.1186/s13287-022-02848-6

[51] Zhang С, Huang L, Wang X, et al. Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up. Stem Cell Res Ther. 2022;13(1):451–465. doi: 10.1186/s13287-022-03143-0

[52] Zhang С., Huang L., Wang X., et al. Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up // Stem Cell Res Ther. 2022. Vol. 13, N 1. P. 451–465. doi: 10.1186/s13287-022-03143-0

[53] Petrou P, Yael G, Zohar A, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis. Neurololy. 2016;73(3):337–344. doi: 10.1001/jamaneurol.2015.4321

[54] Petrou P., Yael G., Zohar A., et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis // JAMA Neurol. 2016. Vol. 73, N 3. P. 337–344. doi: 10.1001/jamaneurol.2015.4321

[55] Master YL, Wei-Meng Tian B, Xing-Fang Jin M, et al. A clinical research of 11cases of human umbilical cord mesenchymal stem cells for curing senile vascular dementia. Transpl Immunol. 2022;74:101669. doi: 10.1016/j.trim.2022.101669

[56] Master Y.L., Wei-Meng Tian B., Xing-Fang Jin M., et al. A clinical research of 11cases of human umbilical cord mesenchymal stem cells for curing senile vascular dementia // Transpl Immunol. 2022. Vol. 74. P. 101669. doi: 10.1016/j.trim.2022.101669

[57] Świątkowska-Flis B, Zdolińska-Malinowska I, Sługocka D, et al. The use of umbilical cord-derived mesenchymal stem cells in patients with muscular dystrophies: results from compassionate use in real-life settings. Stem Cells Transl Med. 2021;10(10):1372–1383. doi: 10.1002/sctm.21-0027

[58] Świątkowska-Flis B., Zdolińska-Malinowska I., Sługocka D., et al. The use of umbilical cord-derived mesenchymal stem cells in patients with muscular dystrophies: results from compassionate use in real-life settings // Stem Cells Transl Med. 2021. Vol. 10, N 10. P. 1372–1383. doi: 10.1002/sctm.21-0027

[59] Gu J, Huang L, Zhang C, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;3(11):43–53. doi: 10.1186/s13287-019-1545-x

[60] Gu J., Huang L., Zhang C., et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial // Stem Cell Res Ther. 2020. Vol. 3, N 11. P. 43–53. doi: 10.1186/s13287-019-1545-x

[61] Sun JM, Dawson G, Franz L, et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med. 2020;9(10):1137–1146. doi: 10.1002/sctm.19-0434

[62] Sun J.M., Dawson G., Franz L., et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder // Stem Cells Transl Med. 2020. Vol. 9, N 10. P. 1137–1146. doi: 10.1002/sctm.19-0434

[63] Lan X, Sun Z, Chu C, et al. Dental pulp stem cells: an attractive alternative for cell therapy in ischemic stroke. Front Neurol. 2019;10:824–834. doi: 10.3389/fneur.2019.00824

[64] Lan X., Sun Z., Chu C., et al. Dental pulp stem cells: an attractive alternative for cell therapy in ischemic stroke // Front Neurol. 2019. Vol. 10. P. 824. doi: 10.3389/fneur.2019.00824

[65] https://www.ruscord.com/ [Internet]. Associacija Ruskord otkryvaet novuju vehu standartizacii dlja bankov pupovinnoj krovi v Rossii. Available from: https://ruscord.com/bez-kategorii/assocziacziya-ruskord-otkryvaet-novuyu-vehu-standartizaczii-dlya-bankov-pupovinnoj-krovi-v-rossii/ (In Russ).

[66] https://www.ruscord.com/ [интернет]. Ассоциация Рускорд открывает новую веху стандартизации для банков пуповинной крови в России. Доступ по ссылке: https://ruscord.com/bez-kategorii/assocziacziya-ruskord-otkryvaet-novuyu-vehu-standartizaczii-dlya-bankov-pupovinnoj-krovi-v-rossii/

[67] https://www.rosstat.gov.ru/ [Internet]. Rosstat predstavljaet pervuju ocenku VVP za 2022 god. Available from: https://rosstat.gov.ru/folder/313/document/198546 (In Russ).

[68] https://www.rosstat.gov.ru/ [интернет]. Росстат представляет первую оценку ВВП за 2022 год. Доступ по ссылке: https://rosstat.gov.ru/folder/313/document/198546

[69] https://www.rosstat.gov.ru/ [Internet]. Rosstat predstavljaet dannye o estestvennom dvizhenii naselenija v mae 2023 goda. Available from: https://rosstat.gov.ru/folder/313/document/212114 (In Russ).

[70] https://www.rosstat.gov.ru/ [интернет]. Росстат представляет данные о естественном движении населения в мае 2023 года. Доступ по ссылке: https://rosstat.gov.ru/folder/313/document/212114

[71] Crompton K, Godler DE, Ling L, et al. Umbilical cord blood cell clearance post-infusion in immune-competent children with cerebral palsy. Cells Tissues Organs. 2022;10:1–8. doi: 10.1159/000527612

[72] Crompton K., Godler D.E., Ling L., et al. Umbilical cord blood cell clearance post-infusion in immune-competent children with cerebral palsy // Cells Tissues Organs. 2022. Vol. 10. P. 1–8. doi: 10.1159/000527612

[73] Carpenter KLH, Major S, Tallman C, et al. White matter tract changes associated with clinical improvement in an open-label trial assessing autologous umbilical cord blood for treatment of young children with autism. Stem Cells Transl Med. 2019;8(2):138–147. doi: 10.1002/sctm.18-0251

[74] Carpenter K.L.H., Major S., Tallman C., et al. White matter tract changes associated with clinical improvement in an open-label trial assessing autologous umbilical cord blood for treatment of young children with autism // Stem Cells Transl Med. 2019. Vol. 8, N 2. P. 138–147. doi: 10.1002/sctm.18-0251

[75] Laskowitz DT, Bennett ER, Durham RJ, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase I safety study. Stem Cells Transl Med. 2018;7(7):521–529. doi: 10.1002/sctm.18-0008

[76] Laskowitz D.T., Bennett E.R., Durham R.J., et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase i safety study // Stem Cells Transl Med. 2018. Vol. 7, N 7. P. 521–529. doi: 10.1002/sctm.18-0008

[77] Bleich D. Umbilical cord blood and type 1 diabetes: a road ahead or dead end? Diabetes Care. 2009;32(11):2138–2139. doi: 10.2337/dc09-1456

[78] Bleich D. Umbilical cord blood and type 1 diabetes: a road ahead or dead end? // Diabetes Care. 2009. Vol. 32, N 11. P. 2138–2139. doi: 10.2337/dc09-1456

[79] Tyumina OV, Volchkov SE, Ovchinnikov PA. Primenenie gematopoeticheskikh stvolovykh kletok pupovinnoy krovi. Genes and Cells. 2019;14(3):236–237. (In Russ). doi: 10.23868/gc125543

[80] Тюмина О.В., Волчков С.Е., Овчинников П.А. Применение гематопоэтических стволовых клеток пуповинной крови // Гены и клетки. 2019. Т. 14, № 3. С. 236–237. doi: 10.23868/gc125543

[81] Tyumina OV, Volchkov SE, Ovchinnikov PA, et al. Clinical evaluation of the efficiency of allogeneic cord blood transfusion in patients with autism. Genes and cells. 2020;15(3):74–79. (In Russ). doi: 10.23868/202011012

[82] Тюмина О.В., Волчков С.Е., Овчинников П.А., и др. Оценка безопасности и эффективности метода трансфузии аллогенных гемопоэтических клеток пуповинной крови пациентам с расстройством аутистического спектра // Гены и клетки. 2020. Т. 15, № 3. С. 74–79. doi: 10.23868/202011012

RIGHTS & PERMISSIONS

Eco-Vector